Literature DB >> 10911988

The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation.

D M Lonard1, Z Nawaz, C L Smith, B W O'Malley.   

Abstract

Estrogen receptor-alpha (ER alpha) is downregulated in the presence of its cognate ligand, estradiol (E2), through the ubiquitin proteasome pathway. Here, we show that ubiquitin proteasome function is required for ER alpha to serve as a transcriptional activator. Deletion of the last 61 amino acids of ER alpha, including residues that form helix 12, abolishes ligand-mediated downregulation of the receptor as do point mutations in the ligand binding domain that impair coactivator binding. In addition, coactivators also are subject to degradation by the 26S proteasome, but their intrinsic transcriptional activity is not affected. These data provide evidence that protein interactions with ER alpha coactivator binding surfaces are important for ligand-mediated receptor down-regulation and suggest that receptor and coactivator turnover contributes to ER alpha transcriptional activity.

Entities:  

Keywords:  Non-programmatic

Mesh:

Substances:

Year:  2000        PMID: 10911988     DOI: 10.1016/s1097-2765(00)80259-2

Source DB:  PubMed          Journal:  Mol Cell        ISSN: 1097-2765            Impact factor:   17.970


  190 in total

Review 1.  Estrogen receptors: orchestrators of pleiotropic cellular responses.

Authors:  J G Moggs; G Orphanides
Journal:  EMBO Rep       Date:  2001-09       Impact factor: 8.807

2.  Ligand-dependent degradation of retinoid X receptors does not require transcriptional activity or coactivator interactions.

Authors:  D L Osburn; G Shao; H M Seidel; I G Schulman
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

3.  Identification of glucose transporter 4 knockdown-dependent transcriptional activation element on the retinol binding protein 4 gene promoter and requirement of the 20 S proteasome subunit for transcriptional activity.

Authors:  Erina Inoue; Aoi Yamashita; Hirofumi Inoue; Mariko Sekiguchi; Asuka Shiratori; Yuji Yamamoto; Tadahiro Tadokoro; Yoshiko Ishimi; Jun Yamauchi
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

4.  Ligand-dependent degradation of SRC-1 is pivotal for progesterone receptor transcriptional activity.

Authors:  Larbi Amazit; Audrey Roseau; Junaid A Khan; Anne Chauchereau; Rakesh K Tyagi; Hugues Loosfelt; Philippe Leclerc; Marc Lombès; Anne Guiochon-Mantel
Journal:  Mol Endocrinol       Date:  2011-01-27

5.  Phosphorylation by p38MAPK and recruitment of SUG-1 are required for RA-induced RAR gamma degradation and transactivation.

Authors:  Maurizio Giannì; Annie Bauer; Enrico Garattini; Pierre Chambon; Cécile Rochette-Egly
Journal:  EMBO J       Date:  2002-07-15       Impact factor: 11.598

Review 6.  Molecular and cellular determinants of estrogen receptor alpha expression.

Authors:  Joseph J Pinzone; Holly Stevenson; Jeannine S Strobl; Patricia E Berg
Journal:  Mol Cell Biol       Date:  2004-06       Impact factor: 4.272

7.  Cleavage and proteasome-mediated degradation of the basal transcription factor TFIIA.

Authors:  Torill Høiby; Dimitra J Mitsiou; Huiqing Zhou; Hediye Erdjument-Bromage; Paul Tempst; Hendrik G Stunnenberg
Journal:  EMBO J       Date:  2004-07-15       Impact factor: 11.598

8.  Liganded ERα Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation.

Authors:  Maiko Okada; Fumiaki Ohtake; Hiroyuki Nishikawa; Wenwen Wu; Yasushi Saeki; Keiji Takana; Tomohiko Ohta
Journal:  Mol Endocrinol       Date:  2015-09-21

Review 9.  Genome stability roles of SUMO-targeted ubiquitin ligases.

Authors:  J Heideker; J J P Perry; M N Boddy
Journal:  DNA Repair (Amst)       Date:  2009-02-23

10.  p21WAF1/CIP1 selectively controls the transcriptional activity of estrogen receptor alpha.

Authors:  Asmaà Fritah; Cécile Saucier; Jan Mester; Gérard Redeuilh; Michèle Sabbah
Journal:  Mol Cell Biol       Date:  2005-03       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.